U.S. Machinery Stock News

HF Sinclair stock has more than tripled over the past five years, yet its valuation checks still lean cheap, which raises a clear question over how much of that past share price strength is already reflected in today's price. With investors also weighing the planned separation of the Lubricants & Specialties segment and the closure of Canada's largest base oil refinery, the current market value is under close scrutiny. HF Sinclair has delivered a 224.8% return over the last five years, which...

Earnings event in focus for Biogen stock Biogen (BIIB) is back in the spotlight after its second quarter 2026 earnings. The company reported higher sales and revenue, alongside a sharp drop in net income and earnings per share. See our latest analysis for Biogen. The latest earnings have arrived after a period of stronger momentum for Biogen, with a 16.0% year to date share price return and a 61.47% total shareholder return over the past year, despite weaker three and five year total...

Zeta Global Holdings (ZETA) is back in focus after strong second quarter 2026 results and a raised full year outlook, supported by rapid uptake of its AI driven marketing platform. See our latest analysis for Zeta Global Holdings. The latest earnings beat and raised outlook sit against a strong run in Zeta Global Holdings’ stock, with a 90 day share price return of 49.12% and a 1 year total shareholder return of 30.54%, which points to building momentum despite a 1 day pullback of 5.58%. If...

Ferrari stock has delivered a strong 89.8% return over the past five years, yet the latest valuation checks and current market multiples suggest the shares are priced at a premium rather than standing out as a clear bargain. Over five years, Ferrari has returned 89.8%, which puts long term holders in a strong position even though the most recent 1 year return of 8.2% is a decline. Expectations for sustained brand strength and pricing power can support the current valuation. However, any...

Expeditors International of Washington, Inc. reported past second-quarter 2026 results showing revenue of US$3,502.34 million and net income of US$266.23 million, with both revenue and earnings per share higher than a year earlier. Alongside this earnings strength, the company continued its long-running share repurchase activity, completing the buyback program first announced in 2001 while not yet deploying capital under its newer 2026 authorization. We’ll now examine how this strong...

Modine Manufacturing (MOD) stock is in focus after the company reported first quarter sales of US$874.1 million and net income of US$73.9 million, alongside new 2027 net sales growth guidance. See our latest analysis for Modine Manufacturing. Despite the new 2027 net sales guidance and stronger first quarter figures, Modine Manufacturing’s recent share price momentum has cooled. The share price is down 16.44% over 30 days and 29.48% over 90 days, even as the year-to-date share price return is...

Genmab’s latest update put Johnson & Johnson (JNJ) back in focus for many investors, as higher royalty income from Darzalex helped lift Genmab’s first half revenue and its full year guidance. See our latest analysis for Johnson & Johnson. Against this backdrop, Johnson & Johnson’s share price sits at US$256.98, with the stock down 3.84% over the past 30 days but up 16.11% over 90 days and supported by a 53.56% 1 year total shareholder return. This suggests momentum has recently been building...

A. O. Smith (AOS) shares are back in focus after the company posted second quarter 2026 results that showed lower sales and net income year over year and tightened its full year outlook for 2026. See our latest analysis for A. O. Smith. A. O. Smith shares closed at $62.99 after the results, with a 7 day share price return of 5.32% and a 90 day share price return of 7.49%. The 1 year total shareholder return declined 8.82%, suggesting shorter term momentum but weaker longer term...

Why Arteris Stock Is Back In Focus After Q2 Results Arteris (AIP) moved back onto investor watchlists after second quarter 2026 earnings showed higher revenue alongside a wider net loss, and a same day announcement of a new Chief Financial Officer. See our latest analysis for Arteris. Over the past year Arteris has moved sharply higher, with a year to date share price return of 102.95% and a 1 year total shareholder return of 239.63%. This suggests momentum has been building even as quarterly...

Watts Water Technologies stock reacts to earnings, guidance and capital returns Watts Water Technologies (WTS) just delivered second quarter 2026 results, raised its full year guidance, updated investors on share repurchases, and affirmed its quarterly dividend, providing several fresh data points to assess. See our latest analysis for Watts Water Technologies. The earnings beat and raised 2026 guidance appear to have reinforced confidence in Watts Water Technologies, with a 1 day share price...

Why Honeywell International is back in focus after its aerospace spin off Honeywell International (HON) is drawing fresh attention after its former aerospace business, now independent, reported weaker than expected first standalone earnings and cut its sales growth outlook, alongside a sharp year to date share price decline. See our latest analysis for Honeywell International. The latest aerospace spin off results have come at a time when Honeywell International’s share price has fallen about...

Why Getty Realty’s New Accounting Chief Matters For Investors Getty Realty (GTY) has announced a leadership change in its finance function, appointing Nicole Rapport as Vice President and Chief Accounting Officer as of August 16, 2026, replacing long-time executive Eugene Shnayderman. The company states that Shnayderman’s departure does not stem from disagreements over accounting principles, financial reporting, or disclosure. For investors tracking governance and reporting quality, this...

Why Corcept Therapeutics stock is back in focus after Q2 earnings Corcept Therapeutics (CORT) is drawing fresh attention after its July 29 earnings update, which paired detailed second quarter results with higher full year 2026 revenue guidance and a buyback progress report. See our latest analysis for Corcept Therapeutics. Corcept Therapeutics’ share price has eased in the very short term, with a 1 day share price return of 2.48% and a 7 day share price return of 8.76%. However, the 30 day...

Geron (GERN) is back in focus after its second quarter 2026 earnings release, fresh RYTELO revenue guidance for 2026 in the US$220 million to US$240 million range, and a new shelf registration filing. See our latest analysis for Geron. At a latest share price of US$1.57, Geron has seen a 7 day share price return of 17.16% and a 90 day share price return of 12.95%, while the 1 year total shareholder return of 20.77% contrasts with a 3 year total shareholder return that is down 47.84%. This...

With the US economy unexpectedly losing 23,000 jobs in July and rate hike expectations cooling, the market mood has shifted fast. That kind of shock can punish some stocks and quietly set up others for their next chapter. This article walks through three growth stocks from our screener that are closely tied to this news, so you can see where investors may be leaning in or stepping back next. The three stocks below are just a sample, while the full growth screen surfaced 46 more larger...

ESCO Technologies (ESE) has drawn fresh attention after reporting third quarter 2026 earnings, raising full year guidance, reaffirming its dividend, and announcing an agreement to acquire test equipment provider Megger Group Limited. See our latest analysis for ESCO Technologies. At a latest share price of $328.03, ESCO Technologies has seen a 7 day share price return of 5.30% and a year to date share price return of 65.99%. The 1 year total shareholder return of 72.99% and 5 year total...

Xenon Pharmaceuticals Inc. has reported past second-quarter 2026 results showing a net loss of US$110.74 million and basic and diluted loss per share of US$1.11, with a six-month net loss of US$213.04 million and loss per share of US$2.28. Despite wider losses, Xenon’s recent successful pre-NDA meeting with the FDA for azetukalner and its US$1.20 billion cash balance underline its capacity to push multiple late-stage neuroscience programs toward potential regulatory milestones. We’ll now...

In the second quarter of 2026, WisdomTree, Inc. reported revenue of US$177.16 million and net income of US$44.28 million, with both basic and diluted earnings per share from continuing operations increasing compared with the prior year period. Alongside these results, WisdomTree continued returning capital to shareholders through a US$0.03 quarterly dividend and buybacks that have retired more than a quarter of its shares since 2014. Next, we’ll explore how this stronger quarterly...

Energy Transfer (ET) is back in focus after its second quarter 2026 report showed higher sales, net income and earnings per unit, along with a raised cash distribution and upgraded full year adjusted EBITDA outlook. See our latest analysis for Energy Transfer. The strong second quarter and higher cash distribution have come alongside steady share price momentum for Energy Transfer, with the latest close at US$20.67 and a year to date share price return of 24.59%. Over the longer term, total...

Celsius Holdings (CELH) is back in focus after its second quarter 2026 report, which combined higher sales with weaker earnings, and a completed US$166.42 million share buyback program. See our latest analysis for Celsius Holdings. The sharp post earnings drop has left Celsius Holdings with a 1 day share price return of down 18.5%, contributing to a year to date share price return of down 50.2% and a 1 year total shareholder return of down 52.6%. This points to fading momentum despite...

Vertiv Holdings Co has delivered very large long term returns over the past 5 years, yet current checks suggest the stock no longer looks obviously cheap, with an intrinsic value estimate from a Discounted Cash Flow (DCF) model that sits close to the recent share price. After such a strong run, the question for investors is how much of the story around digital and AI data center infrastructure is already reflected in what the market is willing to pay for Vertiv today. Vertiv has returned...

Gap stock has more than doubled over the past three years, yet the current share price of US$20.52 still sits well below what its Discounted Cash Flow (DCF) intrinsic value estimate suggests. Both the intrinsic value work and market multiples are pointing in the same direction, which puts the focus on whether the recent pullback this year has left a genuine valuation gap. Gap has delivered a 113.8% return over the past three years, which means anyone looking at the stock today is assessing...

Trip.com Group Limited recently received an administrative penalty decision from China’s State Administration for Market Regulation and has committed to rectification measures, strengthening governance, and supporting the sustainable development of the travel industry. At the same time, analysts have lowered earnings expectations even as revenue is projected to grow, highlighting pressure on profitability just as regulatory scrutiny intensifies. We’ll now examine how the recent regulatory...

Trinity Capital Inc. has released its second-quarter and six-month 2026 results, showing revenue of US$87.17 million and net income of US$44.41 million for the quarter, both higher than a year earlier, while basic and diluted earnings per share from continuing operations eased to US$0.49. Despite higher revenue and net income for both the quarter and half-year, Trinity’s earnings per share declined versus 2025, highlighting the impact of share issuance or other factors on per‑share...